NorthWest Biotherapeutics Inc (NWBO)

[Troymister]

A phase 2 study gets prominent attention from NY Times:

A drug trial unexpectedly obliterated rectal cancer in every single patient.

A small study of patients with rectal cancer yielded an astonishing result: All of the participants completed the trial with their cancer being undetectable by any kind of exam or scan. None of them had significant side effects. “I believe this is the first time this has happened in the history of cancer,” one of the study’s authors said.

The patients in the study took a drug called dostarlimab, which unmasked cancer cells and allowed the immune system to identify and destroy them. The research will need to be replicated, and it’s unclear how long remission will last.